Thursday, November 3, 2011

Dendreon stock tumbles on Provenge sales forecast

Dendreon stock fell 21.9 percent in after-hours trading Wednesday after the Seattle company said it expected "modest growth" in fourth-quarter sales of its prostate-cancer drug Provenge.Dendreon reported Provenge sales rose 5.6 percent in October to $26.4 million from $25 million in September. But November sales will be "slightly below" October's, CEO Mitch Gold said in a conference call with analysts after the company reported third-quarter results.
Originally published Nov. 2, 2011

No comments:

Post a Comment